Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Allison M. Caban-Holt, Frederick A. Schmitt, C. R. Runyons, R. J. Kryscio, M. S. Mendiondo, M. S. Healey, W. R. Markesbery, C. A. Coltman, J. J. Crowley, P. J. Goodman, J. L. Hartline

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

5 Scopus citations


Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

Original languageEnglish
Title of host publicationResearch and Practice in Alzheimer's Disease
EditorsB. Vellas, E. Giacobini
Number of pages7
StatePublished - 2006

Publication series

NameResearch and Practice in Alzheimer's Disease
ISSN (Print)1284-8360


  • Alzheimer's disease
  • Antioxidants
  • Cognitive screening
  • Prevention
  • Study models

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Aging
  • Geriatrics and Gerontology
  • Biological Psychiatry


Dive into the research topics of 'Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model'. Together they form a unique fingerprint.

Cite this